Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT03298009 Not yet recruiting - Heart Failure Clinical Trials

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Canacardia
Start date: November 1, 2017
Phase: N/A
Study type: Interventional

It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency. Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between. At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.

NCT ID: NCT03297918 Not yet recruiting - Heart Failure Clinical Trials

Impact of a Structural Phonation Training on Respiratory Muscle Function in Patients With Structural Heart Disease

Start date: December 2017
Phase: N/A
Study type: Interventional

Most patients with complex congenital heart disease and cardiomyopathy from acquired heart disease have reduced exercise capacity. Exercise capacity is associated with respiratory muscle strength and function. If structured respiratory muscle training positively influences respiratory muscle function in patients with structural heart disease is not well known. The aim of this study is to investigate whether regular singing lessons and breathing exercises improve respiratory muscle strength in patients with congenital or acquired structural heart disease.

NCT ID: NCT03297164 Not yet recruiting - Heart Failure Clinical Trials

Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment

Start date: October 2017
Phase: N/A
Study type: Observational

The main purpose of this study is to build a multi-center, prospective and regionally representative acute myocardial infarction(AMI) cohort´╝îand build a study platform for heart failure caused by AMI; To explore the 1 year incidence rate of heart failure after AMI given the optimized treatment and the treatment model affecting the incidence rate of heart failure, and finally to reduce the incidence rate of heart failure by 5%.

NCT ID: NCT03296813 Not yet recruiting - Heart Failure Clinical Trials

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

TRANSFORM-HF
Start date: August 14, 2018
Phase: Phase 4
Study type: Interventional

TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.

NCT ID: NCT03296280 Enrolling by invitation - Heart Failure Clinical Trials

Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program

Start date: October 3, 2016
Phase: N/A
Study type: Observational

This VA QUERI Partnered Evaluation Initiative will evaluate the impact of an immersive Point-of-care Ultrasound (POCUS) Training Course on provider skill acquisition and retention; the frequency of POCUS use by trained providers; and the barriers/facilitators to POCUS in the VHA. Data sources include pre- and post-course assessment tools, medical coding data, and course evaluations. Providers that participate in the POCUS Training Course will be compared to control providers from wait-listed facilities. Additionally, participating facilities vs. wait-listed facilities for the POCUS Training Course will be compared. Findings from this project will guide ongoing efforts of the investigators' operating partners, VA Specialty Care Centers of Innovation (SCCI) and the VA Simulation Learning and Research Network (SimLEARN), to develop a national POCUS training program and facilitate implementation of POCUS use system-wide in the VA healthcare system.

NCT ID: NCT03294811 Active, not recruiting - Heart Failure Clinical Trials

A Two-way Communication System to Coach Elderly Patients With Heart Failure

CardioCoach
Start date: May 2014
Phase: N/A
Study type: Interventional

This is an open randomized clinical trial with two study arms. One group, receiving usual care for heart failure, will be compared to another group, receiving usual care plus active telemonitoring interference. When leaving the hospital, the usual care arm receives a document with a predefined medication scheme and advice for the general practitioner (like it is currently done in usual care). The telemonitoring interference in the other study arm consists of a smartphone application to register medication intake and to transmit the data of an automatic blood pressure device and a balance to a central platform. The goal is to improve medication uptitration (angiotensin-converting-enzyme inhibitor (ACE-I) and bètablockers (BB)) in heart failure patients and to improve medication compliance.

NCT ID: NCT03294512 Recruiting - Heart Failure Clinical Trials

Pilot and Feasibility Study of a MAWDS (Medications, Activity, Weight, Diet and Symptoms) Heart Failure Mobile Platform

iMAWDS
Start date: September 28, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to create a smartphone app that delivers the educational content of the current Intermountain MAWDS* program and allows patients to enter and track their MAWDS data within the app; and to determine if a broad-scale project can be conducted within the limits of currently available technology. Information from this study will be used to design a larger study that is powered to assess the association between data obtained via a MAWDS app and heart failure outcomes. (*MAWDS- Medications, Activity, Weight, Diet, Symptoms)

NCT ID: NCT03292653 Not yet recruiting - Clinical trials for Cardiac Failure Aggravated

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure

Start date: November 7, 2017
Phase: Phase 2
Study type: Interventional

Primary Objectives: - Assess the safety and tolerability of sotagliflozin in hemodynamically stable patients hospitalized for worsening of heart failure. - Estimate the effects of sotagliflozin on plasma volume changes in hemodynamically stable patients hospitalized for worsening of heart failure. Secondary Objectives: - Explore the effect of sotagliflozin on erythropoiesis, as assessed by changes in plasma erythropoietin levels, in hemodynamically stable patients hospitalized for worsening of heart failure, compared to placebo. - Explore the effect of sotagliflozin on changes in plasma NT-proBNP levels, in hemodynamically stable patients hospitalized for worsening of heart failure, compared to placebo.

NCT ID: NCT03289637 Not yet recruiting - Clinical trials for Vitamin D Deficiency

Supplementation With Vitamin D to Patients With Heart Failure (D-Heart).

D-Heart
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

In 200 patients with documented systolic heart failure give supplementation with vitamin D in those with a 25-OH- vitamin D < 50nmol/L - or placebo. In those with a vitamin D level <25nmol/L a substitution of 2400IU will be given, and in those with a vitamin D level 25-50nmol/L a substitution of 1600IU will be given. Intervention time 12 months. Biomarkers of heart function, quality of life, and hospitalisation will be analysed.

NCT ID: NCT03289481 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Treatment of HFpEF With Nitrate Supplement

Start date: March 20, 2017
Phase: N/A
Study type: Interventional

The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.